Mucormycosis During Second Wave Of COVID-19 in India: Exploratory Analysis From Tertiary Care Centre Of Uttar Pradesh.
Keywords:Corticosteroids, COVID‐ 19, Diabetes, Mucormycosis, Pandemic, Rhizopus
Background and Objectives: In April and May 2021, India faced massive second wave of COVID-19 pandemic and then became the hotspots of mucormycosis across globe. Hence we planned to do first analysis of mucormycosis in Uttar Pradesh with the objectives to explore the epidemiology, vaccination status, clinical features, microbiological findings, treatment of mucormycosis and outcome. Methods: This was an observational study with patients of mucormycosis at tertiary care centre of Agra district, Uttar Pradesh, India from 20 May 2021 to 15 July 2021.Results: A total of 98 participants’ data was analyzed in this mucormycosis analysis. Patients in our study had median age of 55 years with range from 10 days neonate to 88 years. COVID-19 infection was present in 69.4% of participants and diabetes mellitus was present as underlying co-morbid condition in more than 85% of patients, newly onset diabetes was found in about 10% of cases. 91.8 % of cases were unvaccinated and steroid consumption was present in 59(60%) patients. R. arrhizus was among the most common agent while we found less commonly reported fungi like R.homothallicus, Apophysomyces, Cunninghamella. In terms of outcome of patients with mucormycosis after treatment, 41.8% of cases were successfully treated, 31.6% are under treatment, 10.2% were lost to follow-up and 16.3% of cases expired. Conclusion: Diabetes mellitus was labeled as major predisposing factor and history of vaccination being absent in most patients. Awareness about fungal infections, rigorous monitoring of chronic diseases, judicious use of drugs, early diagnosis and prompt treatment is decisive for better outcome.
How to Cite
Copyright (c) 2021 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.